Pharma Exclusives Pressreleases
New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings
Tuesday, March 25, 2025New study results presented at the European Lung Cancer Congress ELCC to March demonstrate the role of AstraZenecas Tagrisso osimertinib as monotherapy and as the backbone for novel combinations
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing
Friday, March 21, 2025AstraZeneca today announced an investment of billion in Beijing to establish its sixth global strategic RD centre together with major research and manufacturing agreements that will further advance life sciences in China
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
Wednesday, March 19, 2025Servier an independent global pharmaceutical group governed by a nonprofit foundation and Black Diamond Therapeutics Inc Nasdaq BDTX a clinicalstage oncology company developing MasterKey therapies that target families of oncogenic mutations in patien...
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
Monday, March 17, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME
AstraZeneca to acquire EsoBiotec to advance cell therapy ambition
Monday, March 17, 2025AstraZeneca has entered into a definitive agreement to acquire EsoBiotec a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity The EsoBiotec Engineered NanoBody Lentiviral ENaBL platform
Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older
Thursday, March 13, 2025Otsuka Pharmaceutical Europe Ltd Otsuka and H Lundbeck AS Lundbeck today announced that the European Commission EC has approved Rxulti brexpiprazole for the treatment of schizophrenia in adolescents aged years and older Brexpiprazole was previously...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
Wednesday, March 12, 2025Zealand Pharma AS a biotechnology company focused on the discovery and development of innovative peptidebased medicines today announces a global collaboration and license agreement with Roche to develop petrelintide Zealand Pharmas amylin analog with...
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Thursday, March 06, 2025ProBioGen and Marea Therapeutics Inc a clinicalstage biotechnology company harnessing the latest advances in human genetics to develop firstinclass nextgeneration medicines for cardioendocrine diseases today announced the successful completion of a s...
FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
Wednesday, March 05, 2025Roche announced today that the US Food and Drug Administration FDA has accepted the companys supplemental Biologics License Application sBLA for GazyvaGazyvaro obinutuzumab for the treatment of lupus nephritis The filing acceptance is based on positi...
CordenPharma Expands Peptide Platform with >€500m Greenfield Facility Construction in the Basel Region of Switzerland
Wednesday, March 05, 2025Following its July announcement CordenPharma is pleased to share significant progress on its growth initiatives with a billion strategic investment in peptide development and manufacturing The companys ambitious expansion plans are set to propel i...
